Abstract
Sarcomas are malignant mesenchymal tumors of variable aggressiveness characterized by a substantial invasive and metastatic potential. In this review we discuss current results of pharmacological targeting of Rho/ROCK signaling in tumor cells, and the growing evidence supporting the hypothesis that Rho/ROCK dependent amoeboid mode of invasion could play a substantial role in metastatic potential of cells of malignant tumors, particularly of sarcomas. We attempt to cover pharmacological, biological and pathological aspects of the problematic in a multidisciplinary manner, from the views of molecular biology to medical practice. We are presenting evidence that blockade of Rho/ROCK pathway decreases amoeboid tumor cell invasion in vitro and substantially attenuates tumor growth and metastasis in vivo. While ROCK inhibitors have been used for a long time in treatment of cardiovascular diseases, the potential use of ROCK inhibitors to treat cancer metastasis has been considered only very recently. We propose that determination of the invasion mode that prevails in a particular sarcoma tumor, together with appropriate use of Rho/ROCK inhibitors could significantly improve the effectiveness of sarcoma tumor treatment in the future.
Keywords: Sarcoma, Rho, ROCK, invasiveness
Current Cancer Drug Targets
Title: ROCK Inhibitors as Emerging Therapeutic Candidates for Sarcomas
Volume: 10 Issue: 2
Author(s): S. Micuda, D. Rosel, A. Ryska and J. Brabek
Affiliation:
Keywords: Sarcoma, Rho, ROCK, invasiveness
Abstract: Sarcomas are malignant mesenchymal tumors of variable aggressiveness characterized by a substantial invasive and metastatic potential. In this review we discuss current results of pharmacological targeting of Rho/ROCK signaling in tumor cells, and the growing evidence supporting the hypothesis that Rho/ROCK dependent amoeboid mode of invasion could play a substantial role in metastatic potential of cells of malignant tumors, particularly of sarcomas. We attempt to cover pharmacological, biological and pathological aspects of the problematic in a multidisciplinary manner, from the views of molecular biology to medical practice. We are presenting evidence that blockade of Rho/ROCK pathway decreases amoeboid tumor cell invasion in vitro and substantially attenuates tumor growth and metastasis in vivo. While ROCK inhibitors have been used for a long time in treatment of cardiovascular diseases, the potential use of ROCK inhibitors to treat cancer metastasis has been considered only very recently. We propose that determination of the invasion mode that prevails in a particular sarcoma tumor, together with appropriate use of Rho/ROCK inhibitors could significantly improve the effectiveness of sarcoma tumor treatment in the future.
Export Options
About this article
Cite this article as:
Micuda S., Rosel D., Ryska A. and Brabek J., ROCK Inhibitors as Emerging Therapeutic Candidates for Sarcomas, Current Cancer Drug Targets 2010; 10 (2) . https://dx.doi.org/10.2174/156800910791054202
DOI https://dx.doi.org/10.2174/156800910791054202 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer
Current Pharmaceutical Design Antibody Gene Therapy: Getting Closer to Clinical Application?
Current Gene Therapy Oxidative Phosphorylation as a Target to Arrest Malignant Neoplasias
Current Medicinal Chemistry Recent Advances in Developing K-Ras Plasma Membrane Localization Inhibitors
Current Topics in Medicinal Chemistry Mechanisms and Drug Targets for Pancreatic Cancer Chemoprevention
Current Medicinal Chemistry Targeted Delivery of Short Interfering RNAs - Strategies for In Vivo Delivery
Recent Patents on Anti-Cancer Drug Discovery Demystifying MST Family Kinases in Cell Death
Current Molecular Medicine Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy
Current Drug Targets Subject Index To Volume 8
Protein & Peptide Letters Clinical and Radiological Characteristics of SAPHO Syndrome
Current Rheumatology Reviews Pharmacological Implications of MMP-9 Inhibition by ACE Inhibitors
Current Medicinal Chemistry Network Pharmacology of Ayurveda Formulation <i>Triphala</i> with Special Reference to Anti-Cancer Property
Combinatorial Chemistry & High Throughput Screening Withdrawal Notice: Emerging Biomarkers and Contributing Factors of Prostate Cancer
Current Cancer Therapy Reviews Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry Comprehensive Analysis Reveals GPRIN1 is a Potential Biomarker for Non-sm all Cell Lung Cancer
Current Bioinformatics Editorial [Hot Topic: Molecular Targeted Therapy of Gastrointestinal Cancer (Guest Editor: Marcus W. Wiedmann)]
Current Cancer Drug Targets Reversing Agents for ATP-Binding Cassette (ABC) Transporters: Application in Modulating Multidrug Resistance (MDR)
Current Medicinal Chemistry - Anti-Cancer Agents Molecular Approaches to Cervical Cancer Therapy
Current Drug Discovery Technologies Design of Novel Antitumor DNA Alkylating Agents: The Benzacronycine Series
Current Medicinal Chemistry - Anti-Cancer Agents The Potency of Refined Mouse Models: Implications for Clinical Trials
Current Cancer Therapy Reviews